ClinicalTrials.gg
RecruitingNCT07472738Updated Mar 16, 2026

Investigation and Classification of Treatable Traits in Patients With Chronic Airway Diseases

An observational study in Asthma (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD) and Chronic Airway Diseases, sponsored by Beijing Chao Yang Hospital. Recruiting at 1 site in China. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Beijing Chao Yang Hospital · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
950
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
21st of 69
950 · median 407
Started
2025
with 31 others
Observational
69 of 251
32 open now
Primary completion
2027-12
later than 64 of 95 live
Registered
217th of 251
by date
Lead sponsor
5 of 251
Beijing Chao Yang Hospital

Among the 251 studies in Asthma with a site in China, this one is the 21st largest by planned enrollment of the 69 observational ones that give a count, is one of 32 that started in 2025, is one of 69 observational ones, reaches primary completion later than 64 of the 95 other live ones, and was the 217th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This research study focuses on chronic airway diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. These conditions make it difficult for patients to breathe, but breathing difficulty (dyspnea) is often perceived very differently. Some patients may feel severe distress with mild breathing problems, while others might not notice significant breathing issues even when lung function is poor. This difference in perception is termed "dyspnea perception."

The main goal of this study is to understand how dyspnea perception varies among patients with chronic airway diseases. The investigators aim to determine if patients can be grouped into different subtypes based on the perception of breathing difficulties. The study will also investigate how these subtypes relate to other treatable characteristics, such as blood cell counts, allergy test results, and findings from lung function tests and brain scans.

Approximately 800 patients with COPD or asthma and 150 healthy volunteers will participate. Participants will answer questionnaires, undergo lung function tests, provide blood samples, and a subset will undergo a special brain scan (functional MRI). No new treatments will be assigned; instead, these characteristics will be observed and measured over time.

It is hoped that this study will help doctors better understand chronic airway diseases and lead to more personalized management strategies for patients in the future.

Read the detailed description

Participants: The study aims to enroll approximately 800 patients with physician-diagnosed COPD (according to GOLD 2022 criteria) or asthma (according to GINA 2022 criteria), aged 20-75 years, and 150 age-matched healthy controls.

Interventions/Assessments: No investigational interventions will be assigned. Participants will undergo comprehensive assessments at baseline and follow-up visits, including:

Dyspnea perception measurement (using standardized scales). Spirometry, lung volume, and diffusion capacity tests. Fractional exhaled nitric oxide (FeNO) measurement. Blood tests (including complete blood count, total IgE, allergen screening). Health-related quality of life questionnaires (CAT, mMRC, AQLQ, SGRQ). High-resolution computed tomography (HRCT) of the chest. Functional magnetic resonance imaging (fMRI) of the brain (in a subset of participants).

Data on exacerbations, comorbidities, and current medications will be collected.

03

Conditions studied

  • Asthma (Diagnosis)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Chronic Airway Diseases

Keywords

  • Treatable Traits
  • Dyspnea Perception
  • Clinical Phenotyping
  • Observational Study
  • Functional Magnetic Resonance Imaging (fMRI)
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of two groups: 1) a patient cohort of approximately 800 individuals with chronic airway diseases (Chronic Obstructive Pulmonary Disease or Asthma) recruited from hospital clinics and community screening; and 2) a control cohort of approximately 150 healthy volunteers. All participants will be aged between 20 and 75 years.

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria for Chronic Airway Disease Patients:

    1. Age 20-75 years.
    2. Meets the diagnostic criteria for according to the 2022 GOLD guidelines OR meets the diagnostic criteria for asthma according to the 2022 GINA guidelines.
    3. Willing and able to provide .
  • Inclusion Criteria for Healthy Controls:

    1. Age ≥20 years.
    2. No history of asthma symptoms or diagnosis of chronic respiratory diseases such as asthma or COPD.
    3. Willing and able to provide informed consent and comply with the study protocol.

Exclusion Criteria:

  • (applies to all participants):

    1. Respiratory tract infection, COPD acute exacerbation, or asthma acute exacerbation within the past 3 months.
    2. Presence of other diseases causing significant lung tissue destruction, such as severe bronchiectasis or tuberculosis.
    3. History of thoracic or abdominal surgery within the past 3 months.
    4. Heart rate >120 beats per minute.
    5. Ongoing anti-tuberculosis treatment.
    6. Presence of other severe, uncontrolled systemic diseases.
    7. Pregnant or lactating women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
950 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Chronic Airway Diseases Cohort

    Patients with physician-diagnosed COPD or asthma

    Other: Comprehensive Clinical Assessment

  • Healthy Control Cohort

    Age-matched healthy volunteers without chronic respiratory diseases

    Other: Comprehensive Clinical Assessment

Interventions

  • OtherComprehensive Clinical Assessment

    This is an observational study. No interventional treatment is assigned. Participants will undergo a comprehensive clinical assessment protocol, which includes: Measurement of dyspnea perception using standardized scales. Spirometry, lung volume, and diffusion capacity tests. Blood sample collection for complete blood count, total IgE, and allergen-specific IgE screening. Completion of quality of life and respiratory symptom questionnaires (e.g., CAT, mMRC, SGRQ, AQLQ). Fractional exhaled nitric oxide (FeNO) measurement. High-resolution computed tomography (HRCT) of the chest. Functional magnetic resonance imaging (fMRI) of the brain (for a subset of participants). Data on exacerbation history, comorbidities, and current medications will also be collected.

06

What researchers measure

Primary outcomes

  1. Distribution of Dyspnea Perception Scores

    The distribution of dyspnea perception scores at baseline in the chronic airway disease cohort, as measured by the Borg Category-Ratio 10 (CR10) Scale (range 0-10, where higher scores indicate more severe dyspnea) or the Visual Analog Scale (VAS) (range 0-100 mm, where higher scores indicate a worse outcome/greater breathing difficulty).

    Time frame: Baseline

  2. Clinical Phenotypes Based on Dyspnea Perception

    Identification of distinct clinical phenotypes derived from cluster analysis of dyspnea perception scores in combination with other clinical traits and biomarkers

    Time frame: Through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — A definitive plan for sharing individual participant data (IPD) has not been established for this study. The possibility of data sharing is under consideration and will be contingent upon obtaining approval from the institutional review board and ensuring compliance with local data privacy regulations. Further details will be specified in a future update to the registration record if a sharing plan is formalized.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 31 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Mar 16, 2026
StartActual
May 7, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07472738
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
May 7, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 16, 2026

Study contacts

Shuya Huang, M.D.
Contact
17852063100@163.com
+8617852063100
ZIxuan Wu, Master
Contact
17734128891@163.com
+8617734128891
Kewu Huang, M.D.
principal investigator · Beijing Chao Yang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion